Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.

Trial Details

NCT ID

NCT06706401

Phase

PHASE3

Sponsor

Centre Leon Berard

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

Vesanoid
Standard radiotherapy
Tailored radiotherapy
Cisplatin
Cetuximab

Locations (sample)

Lyon, France, France|45.74906,4.84789
Vandœuvre-lès-Nancy, France, France|48.66115,6.17114
Villejuif, France, France|48.7939,2.35992
Angers, France|47.47156,-0.55202
Lille, France|50.63391,3.05512

Key Eligibility Criteria

I1. Male or female patients aged ≥ 18 years old at time of inform consent signature.
I2. Patients with primary head and neck tumour up to, but not crossing the midline, previously untreated with histologically-confirmed squamous cel…
the oropharynx p16-, larynx or hypopharynx : T1/N2a-N2b, T2/N0-N2b, T3/N0-N2b (UICC 8th Ed.), or
the oropharynx p16+ : T1/N1 (multiple nodes), T2-T3/N0-N1 (UICC 8th Ed.).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →